These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 20418470)

  • 1. Pathophysiology of cyclooxygenases in cardiovascular homeostasis.
    Sellers RS; Radi ZA; Khan NK
    Vet Pathol; 2010 Jul; 47(4):601-13. PubMed ID: 20418470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of cyclooxygenase inhibition on the gastrointestinal tract.
    Radi ZA; Khan NK
    Exp Toxicol Pathol; 2006 Nov; 58(2-3):163-73. PubMed ID: 16859903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs.
    Mitchell JA; Warner TD
    Nat Rev Drug Discov; 2006 Jan; 5(1):75-86. PubMed ID: 16485347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays.
    Riendeau D; Charleson S; Cromlish W; Mancini JA; Wong E; Guay J
    Can J Physiol Pharmacol; 1997 Sep; 75(9):1088-95. PubMed ID: 9365818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Coxibs: cyclooxygenase-2 inhibitors].
    Turnheim K
    Wien Klin Wochenschr; 2001 Aug; 113(15-16):558-65. PubMed ID: 11571832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonsteroidal anti-Inflammatory drugs and cardiovascular risk.
    Howard PA; Delafontaine P
    J Am Coll Cardiol; 2004 Feb; 43(4):519-25. PubMed ID: 14975457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Specific cyclo-oxygenase-2 inhibitors in cardiovascular pathology].
    Monsuez JJ
    Arch Mal Coeur Vaiss; 2004 Jun; 97(6):632-40. PubMed ID: 15283037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.
    Riendeau D; Percival MD; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Falgueyret JP; Ford-Hutchinson AW; Gordon R; Greig G; Gresser M; Guay J; Kargman S; Léger S; Mancini JA; O'Neill G; Ouellet M; Rodger IW; Thérien M; Wang Z; Webb JK; Wong E; Chan CC
    Br J Pharmacol; 1997 May; 121(1):105-17. PubMed ID: 9146894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclooxygenase-2-selective nonsteroidal anti-inflammatory drugs inhibit hepatocyte growth factor/scatter factor-induced angiogenesis.
    Sengupta S; Sellers LA; Cindrova T; Skepper J; Gherardi E; Sasisekharan R; Fan TP
    Cancer Res; 2003 Dec; 63(23):8351-9. PubMed ID: 14678996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical pharmacology of robenacoxib: a novel selective inhibitor of cyclooxygenase-2.
    King JN; Dawson J; Esser RE; Fujimoto R; Kimble EF; Maniara W; Marshall PJ; O'Byrne L; Quadros E; Toutain PL; Lees P
    J Vet Pharmacol Ther; 2009 Feb; 32(1):1-17. PubMed ID: 19161451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism.
    Egan KM; Wang M; Fries S; Lucitt MB; Zukas AM; Puré E; Lawson JA; FitzGerald GA
    Circulation; 2005 Jan; 111(3):334-42. PubMed ID: 15655126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COX-1 and COX-2 in health and disease.
    Adelizzi RA
    J Am Osteopath Assoc; 1999 Nov; 99(11 Suppl):S7-12. PubMed ID: 10643175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The involvement of a cyclooxygenase 1 gene-derived protein in the antinociceptive action of paracetamol in mice.
    Ayoub SS; Colville-Nash PR; Willoughby DA; Botting RM
    Eur J Pharmacol; 2006 May; 538(1-3):57-65. PubMed ID: 16674937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selectivity of cyclooxygenase isoform activity and prostanoid production in normal and diseased Han:SPRD-cy rat kidneys.
    Warford-Woolgar L; Peng CY; Shuhyta J; Wakefield A; Sankaran D; Ogborn M; Aukema HM
    Am J Physiol Renal Physiol; 2006 Apr; 290(4):F897-904. PubMed ID: 16234308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New NSAIDS: COX-1, COX-2, what about them?].
    Peretz A
    Rev Med Brux; 1998 Sep; 19(4):A399-402. PubMed ID: 9805982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New insights into COX-2 biology and inhibition.
    Patrignani P; Tacconelli S; Sciulli MG; Capone ML
    Brain Res Brain Res Rev; 2005 Apr; 48(2):352-9. PubMed ID: 15850674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents.
    Kurumbail RG; Stevens AM; Gierse JK; McDonald JJ; Stegeman RA; Pak JY; Gildehaus D; Miyashiro JM; Penning TD; Seibert K; Isakson PC; Stallings WC
    Nature; 1996 Dec 19-26; 384(6610):644-8. PubMed ID: 8967954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An introduction to aspirin, NSAIDs, and COX-2 inhibitors for the primary prevention of cardiovascular events and cancer and their potential preventive role in bladder carcinogenesis: part I.
    Moyad MA
    Semin Urol Oncol; 2001 Nov; 19(4):294-305. PubMed ID: 11769881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of selective cyclooxygenase inhibitors on intestinal epithelial cell mitogenesis.
    Erickson BA; Longo WE; Panesar N; Mazuski JE; Kaminski DL
    J Surg Res; 1999 Jan; 81(1):101-7. PubMed ID: 9889067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sodium salicylate inhibits prostaglandin formation without affecting the induction of cyclooxygenase-2 by bacterial lipopolysaccharide in vivo.
    Giuliano F; Mitchell JA; Warner TD
    J Pharmacol Exp Ther; 2001 Dec; 299(3):894-900. PubMed ID: 11714873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.